Page 1

Allogene THERAPEUTICS Allogene Therapeutics Reports First Quarter 2021 Financial Results May 5 , 2021 CD19 Program Highlights • ⚫ Data from the ALLO - 501 ALPHA Study and ALLO - 501A ALPHA2 Study to be Presented at the American Society of Clinical Oncology ( ASCO ) Annual Meeting • • Longer Term Follow - Up from the ALPHA Study and Consolidation Dosing in Both ALPHA and ALPHA2 Study to be Included Allogene to Host Virtual CD19 Forum to Review ASCO Datasets on May 19 , 2021 at 2:30 p.m. PT / 5 : 30 p.m. ET BCMA Program Highlights • FDA Granted RMAT Designation to ALLO - 715 , the First for an AlloCAR TTM Candidate for Relapsed / Refractory Multiple Myeloma • Initiated Combination Arm of the UNIVERSAL Trial with ALLO - 715 and Nirogacestat • FDA Cleared IND Application for ALLO - 605 , the First TurboCAR ™ T Cell Candidate Targeting BCMA for Patients with Relapsed / Refractory Multiple Myeloma Solid Tumor Program Highlights • TRAVERSE Trial Initiated for ALLO - 316 ( anti - CD70 ) in Patients with Advanced or Metastatic Renal Cell Carcinoma • Ended First Quarter with $ 964 Million in Cash , Cash Equivalents and Investments . Quarterly Conference Call and Webcast Scheduled for 2:00 PM PT / 5 : 00 PM ET SOUTH SAN FRANCISCO , Calif . , May 05 , 2021 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics , Inc. ( Nasdaq : ALLO ) , a clinical - stage biotechnology company pioneering the development of allogeneic CART ( AlloCAR TTM ) therapies for cancer , today provided a corporate update and reported financial results for the quarter ended March 31 , 2021 . " We've had a strong start to the year as evidenced by the significant clinical and regulatory progress made across our growing AlloCAR T portfolio , including the start of our first solid tumors study , " said David Chang , M.D. , Ph.D. , President , Chief Executive Officer and Co - Founder of Allogene . " We believe our progress demonstrates our ability to advance the field of allogeneic CAR T cell therapy and we look forward to sharing data from our CD19 program on May 19th during our virtual forum event . " Pipeline Highlights Anti - CD19 Program • Updated data from the dose escalation Phase 1 ALPHA study of ALLO - 501 in relapsed / refractory non - Hodgkin lymphoma ( NHL ) will be jointly presented with initial data from the ALPHA2 study of ALLO - 501A at the American Society of Clinical Oncology ( ASCO ) annual meeting . The presentation will include longer - term follow - up from the initial cohort of patients reported at ASCO 2020 , additional data on patients treated subsequent to ASCO 2020 , dose escalation data from ALPHA2 , and initial results from patients treated with consolidation dosing of ALLO - 501 and ALLO - 501A . A separate poster presentation will detail safety and biomarker findings from ALLO - 647 , Allogene's wholly owned antibody used for lymphodepletion with fludarabine ( Flu ) / cyclophosphamide ( Cy ) in patients with relapsed / refractory NHL and multiple myeloma . • Subject to further study progress and data , the Company plans to initiate a potentially pivotal Phase 2 trial of ALLO - 501A by the end of 2021 . • On May 19 , 2021 , the Company will host a virtual CD19 Forum focused on clinical data being presented at ASCO , along with the Company's vision for the future of CAR T therapy . In addition to presentations from Company management , the Forum will include a discussion with clinical investigators . Anti - BCMA Program The Company continues to execute on its portfolio of anti - B cell maturation antigen ( BCMA ) therapies in patients with multiple myeloma ( MM ) . • ALLO - 715 UNIVERSAL Trial o The U.S. Food and Drug Administration ( FDA ) granted Regenerative Medicine Advanced Therapy ( RMAT )